<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438603</url>
  </required_header>
  <id_info>
    <org_study_id>XHEC-C-2020-070</org_study_id>
    <nct_id>NCT04438603</nct_id>
  </id_info>
  <brief_title>The Role of T/B Cell Repertoire in Non-invasive Diagnosis and Disease Monitoring in Patients With IgA Nephropathy</brief_title>
  <official_title>The Role of T/B Cell Repertoire in Non-invasive Diagnosis and Disease Monitoring in Patients With IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study aims to investigate the role of IR-Seq in non-invasive diagnosis and
      disease monitoring in patients with IgA nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmunity may play an important role in IgA nephropathy, and previous studies have shown
      that immune repertoire sequencing (IR-Seq) may help elucidate the dynamic changes of immune
      repertoire (IR) in autoimmune disease states. To further explore the potential application
      value of this technology, we will conduct a series of prospective studies to investigate the
      role of IR-Seq in non-invasive diagnosis and disease monitoring in patients with IgA
      nephropathy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 17, 2020</start_date>
  <completion_date type="Anticipated">August 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary protein remission rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Including complete and partial remission rate of urinary protein. Complete remission criteria: post-treatment urine protein &lt;0.3 g/24h; partial remission criteria: post-treatment urine protein &lt;50% of the maximum value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour urine protein level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR (estimated using the 2009 CKD-EPI formula)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>non-progressive IgA nephropathy</arm_group_label>
    <description>n = 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progressive IgA nephropathy</arm_group_label>
    <description>n = 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <description>n=10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention for non-progressive IgA nephropathy</intervention_name>
    <description>Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of &lt; 130/80 mm Hg</description>
    <arm_group_label>non-progressive IgA nephropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention for progressive IgA nephropathy</intervention_name>
    <description>BP-lowering goal of &lt; 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:
If GFR&gt;60 ml/min/1.73m^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.
If GFR is 30-60 ml/min/1.73m^2, intravenous cyclophosphamide (CTX) 750 mg per month per m^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks.</description>
    <arm_group_label>progressive IgA nephropathy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples; Blood samples taken using PAXgene vacuum blood collection tubes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. IgA nephropathy:

          1. Age: 18-70 years.

          2. Patients diagnosed with primary IgA nephropathy by renal biopsy.

          3. Estimated glomerular filtration rate (using the 2009 CKD-EPI formula)
             â‰¥30ml/min/1.73/m^2.

          4. Obtain informed consent from patients. 2. Healthy Control: Gender, age and ethnicity
             matched health volunteers. 3. IgAN patients were further divided into
             non-progressive/progressive groups, as defined below:

        1) Non-Progressive Patients:

        a. Annual eGFR loss rate &lt;3ml/min/1.73m^2. b. Urinary protein &lt; 1 g/24h. c. Oxford
        Classification MEST-C score &lt;3. 2) Progressive patients:

          1. Does not meet the above definition of non-progressive patient.

          2. Annual eGFR loss rate &gt;5ml/min/1.73m^2 and/or eGFR decrease of more than 50% from
             baseline (in the absence of other possible causes of kidney damage).

          3. Urinary protein &gt; 1 g/24h.

        Exclusion Criteria:

          1. Patients with malignant tumours or severe liver disease;

          2. Patients with secondary IgAN such as systemic lupus erythematosus (SLE), hepatitis
             B-associated nephropathy, etc.;

          3. During pregnancy or lactation;

          4. After kidney transplantation;

          5. More than one serious acute infection in the psat 12 months (including but not limited
             to peritonitis, cellulitis, pneumonia, etc.);

          6. Chronic infection (including but not limited to tuberculosis, HIV, hepatitis B, etc.);

          7. Use of glucocorticosteroids and other immunosuppressive drugs within the last 6
             months;

          8. Incomplete medical history or clinical data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Gengru</last_name>
      <phone>+86-13917983703</phone>
      <email>nephox@sjtu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgA Nephropathy</keyword>
  <keyword>IR-Seq</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

